comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 21:25:21 - browse：63

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： What we owe ALS patients — and why one company fell short

WSS

Setback for rare diseases as Taysha Gene Therapies pulls back

Telehealth options flood the market as retailers push virtual care

Why Sanofi got shellacked over its spinoff

The pink breast cancer awareness ribbon needs a redesign

CDC recommends rationing of RSV shot due to shortages

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

focus

comprehensive

hotspot

Affirmative action in medical school literally saved lives

RSV injection headlines need to be accurate for good uptake

Dobbs anniversary: the lost opportunity of abortion as health care

What we owe ALS patients — and why one company fell short

How one medical school became remarkably diverse

Eli Lilly to pay $200M for Beam’s stake in gene

In age of alternative facts, a scholarly course on calling out crap

Setback for rare diseases as Taysha Gene Therapies pulls back

In Memoriam: Notable people who died in 2023

Health insurers' Q3 question: how much care are people getting?

entertainment

Biden's order seeks to regulate AI risk without stifling innovation

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Congress extends some pandemic preparedness programs

Health insurers' Q3 question: how much care are people getting?

Medicare innovation center doesn’t save money, experts say

CRISPR base editing slashes cholesterol levels in monkeys

focus

explore

leisure time

hotspot